The Hindu Business Line : Sunday, October 17, 2004

ANNOUNCEMENTS
JK Pharma suspends production in TN plant
JK PHARMACHEM has announced that it had decided to suspend production at its Penicillin-G plant in Cuddalore, Tamil Nadu, because Chinese imports had made it difficult to sustain operations. In a notice to the Bombay Stock Exchange, the company ... More

Dishman Pharma securitises future earnings from deal with European co
The securitisation deal will also help Dishman to build future funding relationships with multi-national financial institutions. More

GM India opens call centre

Lupin withdraws rofecoxib

NEW PROJECTS
Moser Baer to invest $13 m to set up facility in Germany
MOSER Baer India Ltd is in the process of setting up manufacturing operations in Germany at an investment of $12-13 million (Rs 54.9 crore - Rs 59.5 crore). "We are setting up a manufacturing operation in Germany in Thueringia, for which we ... More

ALLIANCES & JOINT VENTURES
Glenmark gets $10 m from Ireland co in drug deal
GLENMARK Pharmaceuticals India Ltd (GPIL) has received an upfront payment of $10 million from Ireland's Forest Laboratories for a drug licensing deal that the two companies had signed in September this year. Glenmark Pharmaceuticals SA ... More

OUTLOOK
Lanka IOC expects 4-fold increase in net
LANKA IOC, a subsidiary of Indian Oil Corporation, expects to achieve a four-fold increase in its net profit for the current year. The company's Managing Director, Mr M. Nageswaran, said on Saturday that the net profit was projected to ... More

Scoreboard
SE Diary

Comments & Letters to the Editor to: bleditor@thehindu.co.in
Subscribe to: Business Line

Pick a Winner Stock Market Contest

Top Stories
Forex reserves up $20 m

Demand for Indian tobacco may rise

Cement consumption in South may pick up in second half

Looking back
Oct. 10-Oct. 16
Gujarat Ambuja on capacity expansion drive

Indian cos' overseas acquisitions set to go up

ONGC plans foray into oil recovery consultancy

PTC unfazed by competition

Global oil price rise may add to drug industry input costs